Skip to main content

Table 2 Subgroup analyses of various factors related to achieving pathologic complete response

From: Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy

Category Number of studies (references) Summary estimate odds ratio (95% CI) Heterogeneity, I2(%) pCR rate (95% CI)
TNBC (%) Heterogeneity, I2(%) non-TNBC (%) Heterogeneity, I2(%)
Cycles of NAC        
<4 cycles 2 [13, 25] 5.27 (2.57, 10.79) 0 19.6 (13.5, 27.6) 0 4.6 (2.7, 7.8) 0
4 cycles 6 [15, 21, 28, 33, 34, 45] 3.51 (2.21, 5.57) 0 29.2 (23.0, 26.3) 41.4 15.0 (11.8, 18.8) 35.1
6 cycles 3 [17, 27, 30] 3.10 (1.84, 5.22) 35 27.6 (20.3, 36.3) 0 11.0 (8.2, 14.7) 41.3
>6 cycles 3 [8, 26, 29] 2.77 (1.66, 4.61) 41 36.8 (28.8, 45.6) 33.8 17.8 (13.4, 23.3) 0
Types of NAC regimen       
Anthracycline-based 19 [1, 8, 9, 1214, 1618, 2534] 3.19 (2.63, 3.88) 7 26.8 (24.1, 29.6) 39.8 12.1 (10.8, 13.5) 43.2
Taxane-containing 10 [8, 13, 18, 19, 21, 25, 26, 29],[33, 45] 3.29 (2.41, 4.48) 0 30.5 (25.9, 35.5) 38.2 14.9 (12.6, 17.5) 44.8
Platinum-containing 4 [17, 19, 21, 45] 3.10 (1.59, 6.03) 0 44.2 (30.8, 58.5) 31.1 21.3 (16.3, 27.3) 43.6
Gemcitabine-containing 2 [15, 31] 3.49 (1.42, 8.57) 0 44.5 (29.3, 60.8) 0 18.8 (11.2, 29.8) 30.2
The number of drug in NAC       
Two kinds of drugs 9 [13, 15, 19, 21, 25, 27, 32, 33],[45] 3.89 (2.75, 5.49) 0 28.7 (23.8, 34.2) 36.3 12.9 (10.7, 15.5) 46.1
Three kinds of drugs 4 [14, 17, 26, 34] 2.39 (1.77, 3.23) 16 22.5 (18.8, 26.5) 19.8 11.2 (9.5, 13.3) 43.6
Four kinds of drugs 4 [8, 9, 29, 31] 4.83 (2.80, 8.35) 0 45.7 (35.8, 55.9) 0 15.5 (11.4, 20.6) 0
Total treatment duration of NAC       
<12 weeks 2 [13, 25] 5.27 (2.57, 10.79) 0 19.6 (13.5, 27.6) 35.4 4.6 (2.7, 7.8) 0
12 weeks 7 [14, 15, 21, 28, 30, 33, 34] 3.42 (2.34, 4.99) 0 24.9 (20.5, 29.9) 42 13.3 (10.7, 16.3) 42.6
16 weeks 2 [19, 45] 2.88 (1.27, 6.56) 0 44.2 (28.4, 61.3) 41.4 24.8 (17.7, 33.7) 46.7
>16 weeks 6 [8, 17, 24, 26, 27, 29] 3.47 (2.80, 4.30) 7 37.6 (34.0, 41.2) 25.8 14.7 (12.9, 16.6) 38
NAC schedules        
Conventional chemotherapy 8 [1315, 17, 21, 25, 27, 45] 4.40 (3.02, 6.42) 0 24.1 (19.8, 29.0) 35.6 9.7 (7.7, 12.1) 44.5
Sequential chemotherapy 4 [8, 26, 29, 31] 2.96 (1.85, 4.72) 20 37.4 (30.0, 45.5) 22.5 17.2 (13.2, 22.1) 0
  1. CI, confidence interval; NAC, neoadjuvant chemotherapy; pCR, pathologic complete response; TNBC, triple-negative breast cancer.